Innate Pharma (IPHA) Equity Ratio (2017 - 2025)
Historic Equity Ratio for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to 0.06.
- Innate Pharma's Equity Ratio fell 7088.05% to 0.06 in Q2 2025 from the same period last year, while for Jun 2025 it was 0.01, marking a year-over-year decrease of 7453.63%. This contributed to the annual value of 0.08 for FY2024, which is 7315.09% down from last year.
- Innate Pharma's Equity Ratio amounted to 0.06 in Q2 2025, which was down 7088.05% from 0.08 recorded in Q4 2024.
- In the past 5 years, Innate Pharma's Equity Ratio registered a high of 0.5 during Q2 2021, and its lowest value of 0.06 during Q2 2025.
- Over the past 5 years, Innate Pharma's median Equity Ratio value was 0.29 (recorded in 2023), while the average stood at 0.28.
- As far as peak fluctuations go, Innate Pharma's Equity Ratio skyrocketed by 1372.2% in 2023, and later crashed by 7315.09% in 2024.
- Quarter analysis of 5 years shows Innate Pharma's Equity Ratio stood at 0.4 in 2021, then crashed by 35.14% to 0.26 in 2022, then rose by 13.72% to 0.3 in 2023, then plummeted by 73.15% to 0.08 in 2024, then crashed by 30.42% to 0.06 in 2025.
- Its Equity Ratio stands at 0.06 for Q2 2025, versus 0.08 for Q4 2024 and 0.19 for Q2 2024.